Recruiting
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors - CA238-0001
Updated: 29 April, 2025 | ClinicalTrials.gov
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria: - Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1. - CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:. i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated). - NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:. i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease. ii) Progressed on at least 2 prior lines of therapy, iii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available. - GC: Part 2A-NSCLC/GC, 2L+ GC:. i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy). ii) ECOG performance status of 0 or 1. Exclusion Criteria: - History of anaphylactic reactions to irinotecan and/or bevacizumab. - Previously received therapy targeting CEACAM5. - Grade ≥ 3 ILD/pneumonitis. - Other protocol-defined Inclusion/Exclusion criteria apply.
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001
